Acquisition strengthens Petauri's global expertise in generating, demonstrating, and communicating product value

此次收购增强了Petauri在生成、展示和传播产品价值方面的全球专业能力

NASHVILLE, Tenn.

田纳西州纳什维尔

,

，

Oct. 8, 2026

2026年10月8日

/PRNewswire/ -- Petauri, a purpose-built pharmaceutical services platform, today announced the acquisition of Franklin Pharmaceutical Consulting (FPC), a specialized health economics and outcomes research (HEOR), real-world evidence (RWE), and market access consultancy. The acquisition strengthens Petauri's ability to support life sciences companies in generating evidence, communicating product value, and navigating complex access and reimbursement decisions..

/美通社/ -- 专为制药服务打造的平台Petauri今日宣布收购富兰克林制药咨询公司（FPC），这是一家专注于卫生经济学与结果研究（HEOR）、真实世界证据（RWE）以及市场准入的咨询机构。此次收购将增强Petauri支持生命科学公司生成证据、传达产品价值以及应对复杂的准入和报销决策的能力。

With decades of scientific and commercial leadership experience, FPC has provided strategic and tactical support for HEOR, medical, and market access teams across the product life cycle. FPC's expertise includes HEOR and RWE strategies, scientific payer-value communications, and payer-focused tools and dossiers that demonstrate the value of innovative medicines..

凭借数十年的科学与商业领导经验，FPC 在产品生命周期内为卫生经济学与结果研究（HEOR）、医学事务及市场准入团队提供战略与战术支持。FPC 的专业专长涵盖 HEOR 与真实世界证据（RWE）策略、面向支付方的科学价值沟通，以及旨在展示创新药物价值的支付方导向工具与申报档案。

'Franklin Pharmaceutical Consulting is an outstanding addition to Petauri and a natural extension of our vision for Petauri Evidence,' said Dan Renick, CEO of Petauri. 'FPC brings deep expertise in translating HEOR and market access evidence into practical strategies and communications for a wide range of access decision-makers.

“富兰克林制药咨询公司（Franklin Pharmaceutical Consulting）是佩陶里（Petauri）的重要补充，也是我们对‘佩陶里证据’（Petauri Evidence）愿景的自然延伸。”佩陶里首席执行官丹·雷尼克（Dan Renick）表示。“富兰克林制药咨询公司在将卫生经济学与结果研究（HEOR）及市场准入证据转化为面向各类准入决策者的实用策略和沟通方案方面，拥有深厚的专业知识。

Aligning FPC's strengths with our existing capabilities creates a more connected platform to support clients from evidence planning through commercialization and life cycle management.'.

将FPC的优势与我们现有的能力相结合，打造一个更加互联的平台，支持客户从证据规划到商业化及生命周期管理的全过程。

'Our clients rely on us for senior-level expertise with solutions tailored to their evidence and access challenges,' said Meg Franklin, PharmD, PhD, founder of FPC. 'We are excited to join the Petauri team and expand the global capabilities available to our clients while maintaining the scientific rigor, collaboration, and hands-on partnership they value.' Dr.

“我们的客户依赖我们提供资深专家级的专业知识，并为其在证据生成和市场准入方面的挑战量身定制解决方案，”FPC 创始人 Meg Franklin 药学博士、哲学博士表示。“我们很高兴加入 Petauri 团队，在保持客户所重视的科学严谨性、协作精神和务实合作伙伴关系的同时，进一步拓展我们为客户提供的全球服务能力。”

Franklin will serve as President, Petauri Evidence US..

富兰克林将担任总统，佩陶里证据美国..

'Evidence has its greatest impact when it helps access decision-makers recognize a treatment's value,' said Joette Gdovin, PhD, MPA, Partner at FPC, now EVP, Evidence & Value, Petauri Evidence US. 'Together with Petauri, we will connect evidence generation, value communication, and market access strategies from the start, helping clients reduce barriers and secure access to meaningful treatment options for patients.'.

“当证据有助于市场准入决策者认识到治疗价值时，其影响力最大。”FPC合伙人、现任Petauri Evidence US执行副总裁兼证据与价值负责人Joette Gdovin博士（PhD, MPA）表示。“我们将与Petauri携手，从伊始便将证据生成、价值传播和市场准入策略相衔接，帮助客户减少障碍，确保患者能够获得有意义的治疗选择。”

About Petauri

关于 Petauri

Petauri is a purpose-built pharmaceutical services platform based in Nashville, Tennessee. Founded by CEO Dan Renick in partnership with Oak Hill Capital, the platform is launching, acquiring, and combining best-in-class companies with recognized expertise in life sciences, health systems, scientific communications, and market access..

Petauri 是一家总部位于田纳西州纳什维尔的专业化制药服务平台。该平台由首席执行官丹·雷尼克（Dan Renick）与橡树山资本（Oak Hill Capital）合作创立，旨在启动、收购并整合在生命科学、医疗体系、科学传播和市场准入领域拥有公认专业知识的行业领先企业。

Since itsfounding in 2023, the platform has launched Petauri Advisors and acquired The Kinetix Group, the agencies of FORCE Communications, Mtech Access, Delta Hat, the agencies of the Brightly Network, Formulary Insights, and Artia Solutions, all now Powered by Petauri™. The legacy organizations now comprise Petauri's six business units: Petauri Advance, Petauri Advisors, Petauri Evidence, Petauri Kinect, Petauri MAx, and Artia Solutions.

自2023年成立以来，该平台推出了Petauri Advisors，并收购了The Kinetix Group、FORCE Communications旗下机构、Mtech Access、Delta Hat、Brightly Network旗下机构、Formulary Insights以及Artia Solutions，这些机构现在均由Petauri™赋能。这些原有组织如今构成了Petauri的六大业务部门：Petauri Advance、Petauri Advisors、Petauri Evidence、Petauri Kinect、Petauri MAx和Artia Solutions。

Oak Hill will invest more than $250 million of equity capital in this initiative from its latest fund (OHCP VI). The platform works with pharmaceutical and life sciences clients to improve patient outcomes by establishing the scientific, economic, humanistic, and societal value of medical advances..

橡树山将从其最新基金（OHCP VI）中向该计划投入超过2.5亿美元的股权资本。该平台与制药和生命科学客户合作，通过确立医学进步在科学、经济、人文和社会方面的价值，改善患者预后。

From strategy to implementation, Petauri seamlessly supports these clients with a wide range of innovative solutions that speed patient access to life-changing care. For more information, please visit

从战略到实施，Petauri 通过广泛的创新解决方案无缝支持这些客户，加速患者获得改变生命的治疗。如需更多信息，请访问

www.petauri.com

www.petauri.com

.

。

Liz Gulino

莉兹·古利诺

[email protected]

[email protected]

(917) 410-1162

(917) 410-1162

SOURCE Petauri

来源 Petauri

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示